Assistant Research

Natalie Elizabeth Goldberger

**** ***** ********* **. *** B

Arlington, VA 22206

301-***-**** (Mobile)

*************@*****.***

http://www.linkedin.com/pub/natalie-goldberger/12/b36/7a4

_____________________________________________________________________________

PROFILE

Experienced and innovative cancer research scientist with a high level of achievement independently leading a wide array of research projects focused on biochemical analysis, expression profiling and biomarker discovery is seeking a challenging and rewarding translational research position.

AREAS OF EXPERTISE, CORE COMPETENCIES

• Biomarker identification in breast and prostate cancer using cDNA, miRNA and tissue microarrays, combined with immunohistochemistry (IHC) and immunofluorescence (IF) microscopy.

• Biomarker validation using stable cell lines generated via lentivirus, transfection with siRNAs, cell-based assays, FACS analysis, qRT-PCR and in vivo cancer models.

• Genomics analysis of cancer cell lines, and clinical tissue and blood samples, using sequencing, FISH, PCR, CGH array, and RNA expression analysis.

• Proteomics analysis using the ion trap mass spectroscopy to characterize protein complexes, post-translational modifications and structural conformations after recombinant protein expression, affinity purification, and immunoprecipitation (IP).

PROFESSIONAL EXPERIENCE

Postdoctoral Research Fellow, Biomarker Discovery in Breast Cancer

National Institutes of Health (Bethesda, MD) National Cancer Institute, Laboratory of Cancer Biology & Genetics

April, 2008 – April, 2012

Research Focus: Identification of microRNA (miRNA) associated with breast cancer tumorigenesis and metastasis

Spotlighted Achievements:

• Profiled miRNA expression levels in primary mammary tumors from AKXD (AKR/J x DBA/2J) recombinant inbred mice using miRNA microarrays.

• Correlated miRNA expression profiles with metastatic index to identify candidate tumor and metastasis suppressing miRNAs.

• Utilized a lentiviral vector system to create stable cells lines that expressed candidate miRNAs.

• Performed in vivo and in vitro analysis of stable cell lines to validate the tumor and metastasis suppressor functions of each candidate miRNA.

- In vivo analysis: Conducted quantitative analysis of metastatic lungs and primary mammary tumors from mice after orthotopic injection.

- In vitro analysis: Conducted cellular proliferation and migration assays, cell cycle analysis using flow cytometry (FACS), and senescence detection with β-galactosidase.

Research Assistant, Biochemistry of the Androgen Receptor

Ohio State University (Columbus, OH)

College of Pharmacy, Biophysics Department

June, 2002 - April, 2008

Research Focus: Identification of the molecular mechanisms driving selective androgen receptors (SARM) tissue-selectivity

Spotlighted Achievements:

• Characterized the structural conformation, post-translational modifications and protein-protein interactions associated with SARM-bound androgen receptor (AR) using LCQ DECA ion trap mass spectroscopy.

• Utilized immunofluorescence microscopy to observe the subcellular location and cytoplasm-nuclear transport properties of SARM-bound androgen receptor.

• Performed immunoprecipitation to confirm the association of SARM-bound AR with multiple ligand-specific proteins.

Biologist, Biomarker Discovery in Breast and Prostate Cancer

National Institutes of Health (Bethesda, MD)

National Human Genome Research Institute, Cancer Genetics Branch

July, 1999 - June, 2002

Research Focus: Identification of biomarkers associated with prostate cancer or breast cancer progression

Spotlighted Achievements:

• Validated candidate genes driving the 17q23 amplicon in human breast cancer by utilizing cDNA microarrays, tissue microarrays and fluorescene in situ hybridization (FISH).

• Identified genes involved in prostate cancer progression within the CWR22 prostate tumor xenograft model through siRNA knock down, cDNA microarray analysis, apoptosis detection, and immunohistochemistry on tissue microarrays.

Clinical Research Assistant, Clinical Mutation Identification

Georgetown University Medical Center (Washington, DC)

Institute for Molecular and Human Genetics

July, 1998 - June, 1999

Research Focus: Identification of mutations and polymorphisms in genes MLH1 and MSH2

Spotlighted Achievements:

• Discovered novel polymorphisms while utilizing ABI 377 DNA sequencing analysis to screen for mutations and polymorphisms within the MLH1 and MSH2 genes of individuals at risk for hereditary nonpolyposis colon cancer (HNPCC).

LEADERSHIP SKILLS

- Mentored a Howard Hughes Medical Institute research scholar (June, 2010 – April, 2012)

- Supervised an undergraduate’s summer research project (June, 2009 – August, 2009)

- Supervised an undergraduate’s honors thesis research project (September, 2006 – March, 2008)

COMMUNICATION SKILLS

- Writer for the Office of Intramural Training and Education, NIH (April, 2011 – April, 2012)

- Writer for NIH Catalyst, A Publication for Intramural Scientist, NIH (May, 2009 – April, 2012)

- Invited guest speaker for the Models of Human Cancers Consortium (MMHCC) meeting (June, 2011)

- Invited guest speaker for the Ohio University Physics Program (January 2007)

COMPUTER SKILLS

Office Applications: Excel, Word, PowerPoint, Adobe Photoshop

Programming Languages: JAVA and C++

Scientific Applications: Partek Genomics Suite, Ingenuity Pathways Analysis, GraphPad Prism, Sequence Navigator, BLAST, GenBank, SEQUEST

EDUCATION

PhD, Biophysics The Ohio State University Columbus, OH

BS, Biochemistry University of Delaware Newark, DE

Phi Beta Kappa, Cum Laude

PUBLICATIONS

1. Goldberger N, Walker R, Winter S, and Hunter KW. ES cell microRNA miR-290 suppresses breast cancer progression, targets breast cancer biomarker Arid4b and stimulates estrogen receptor signaling. Ready for submission.

2. Goldberger N, Walker R, Hudson R, and Hunter KW. Classification of miR-132 as a breast cancer progression suppressor. In preparation.

3. Goldberger N, Hunter KW. A systems biology approach to defining metastatic biomarkers and signaling pathways. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2009; 1: 89-96.

4. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, and Abagyan R. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. PNAS 2007; 104:11927-32.

5. Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R, Goldberger N, Elkahloun AG, Willi N, Koivisto P, Ferhle W, Raffeld M, Sauter G, and Kallioniemi O-P. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Research 2002; 62:1256-60.

6. Rozenblum E, Vahteristo P, Sandberg T, Bergthorsson JT, Syrjakoski K, Weaver D, Haraldsson K, Johannsdottir HK, Vehmanen P, Nigam S, Goldberger N, Robbins C, Pak E, Dutra A, Gillander E, Stephan DA, Bailey-Wison J, Hank Juo S-H, Kainu T, Arason A, Barkardottir RB, Nevanlinna H, Borg A, and Kallioiemi O-P. A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes. Human Genetics 2002; 110:111-21.

7. Allander SV, Nupponen N, Ringner M, Hostetter G, Maher GW, Goldberger N, Chen Y, Carpten J, Elkahloun AG, and Meltzer PS. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Research 2001; 61:8624-8.

Contact this candidate